306 related articles for article (PubMed ID: 15570574)
21. [Adverse effects of antidepressants and antimanics].
Tanaka T; Koyama T
Ryoikibetsu Shokogun Shirizu; 2003; (38):362-5. PubMed ID: 12877003
[No Abstract] [Full Text] [Related]
22. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
23. Withdrawal syndromes after paroxetine and sertraline discontinuation.
Fava GA; Grandi S
J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
[No Abstract] [Full Text] [Related]
24. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
25. [Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran].
Koshiishi T; Okuyama K
Yakugaku Zasshi; 2016; 136(12):1675-1679. PubMed ID: 27904101
[TBL] [Abstract][Full Text] [Related]
26. Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.
Arai M
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):137-8. PubMed ID: 12486290
[No Abstract] [Full Text] [Related]
27. More cases of paroxetine withdrawal syndrome.
Pacheco L; Malo P; Aragues E; Etxebeste M
Br J Psychiatry; 1996 Sep; 169(3):384. PubMed ID: 8879736
[No Abstract] [Full Text] [Related]
28. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.
Yoshida K; Higuchi H; Ozaki N
Pharmacopsychiatry; 2007 Mar; 40(2):84-5. PubMed ID: 17447181
[No Abstract] [Full Text] [Related]
29. An acute neurological syndrome with cerebrovascular and parkinsonian clinical features associated with perioperative SNRI withdrawal.
Williams GW; Gandhi SJ; Altamirano A
J Neurosurg Anesthesiol; 2013 Jul; 25(3):353-4. PubMed ID: 23552278
[No Abstract] [Full Text] [Related]
30. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Preskorn SH
J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
[No Abstract] [Full Text] [Related]
31. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
Bernstein CD; Albrecht KL; Marcus DA
Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
[TBL] [Abstract][Full Text] [Related]
32. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
Kito S; Nakajima T; Koga Y
Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
[No Abstract] [Full Text] [Related]
33. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Judge R; Parry MG; Quail D; Jacobson JG
Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
[TBL] [Abstract][Full Text] [Related]
35. Discontinuation of antidepressant therapy: emerging complications and their relevance.
Thompson C
J Clin Psychiatry; 1998 Oct; 59(10):541-8. PubMed ID: 9818638
[No Abstract] [Full Text] [Related]
36. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.
Mease PJ; Zimetbaum PJ; Duh MS; Vekeman F; Guérin A; Boerstoel-Streefland M; Jiang W; Lefebvre P
Ann Pharmacother; 2011 Feb; 45(2):179-88. PubMed ID: 21304035
[TBL] [Abstract][Full Text] [Related]
37. Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipran.
Takahashi H; Ishigooka J
Clin Neuropharmacol; 2009; 32(3):177-8. PubMed ID: 19483494
[No Abstract] [Full Text] [Related]
38. Antidepressants in the postpartum period: additional considerations.
Burbeck R; Pilling S; Tomson D; McDonald L
Am J Psychiatry; 2008 Feb; 165(2):262-3; author reply 263. PubMed ID: 18245193
[No Abstract] [Full Text] [Related]
39. [Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline].
MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526675
[No Abstract] [Full Text] [Related]
40. [Not Available].
Lenz F; Bauer M; Ritter P
Fortschr Neurol Psychiatr; 2018 Sep; 86(9):592-603. PubMed ID: 30248692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
